FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine and may be used to develop therapeutic approaches to cerebral ischemia. That is ensured by simulating cerebral ischemia in rats. The method of treating involves three intraperitoneal injections of human recombinant erythropoietin. The first, second and third injections thereof are carried out 3, 24 and 48 hours after the action that caused cerebral ischemia. The amount of erythropoietin per an injection is 5000 IU/kg. Furthermore, 30-60 minutes after the first dose of erythropoietin has been administered, an ischemic region within its projection is exposed to the diffuse percutaneous infrared laser at wavelength 970 nm, power 1 Wt for 2 minutes at 2-3 cm from the surface.
EFFECT: method provides the considerably higher clinical effectiveness in cerebral ischemia ensured by the specified dose schedule of the preparation and the laser exposure.
8 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING SPINAL ISCHEMIA IN EXPERIMENT | 2012 |
|
RU2496513C1 |
METHOD FOR PREVENTION OF ISCHEMIA OF RETINA WITH ERYTHROPOETIN EXPERIMENTALLY | 2013 |
|
RU2539629C1 |
METHOD FOR STIMULATING NEOANGIOGENESIS IN ISCHEMIC SKELETAL MUSCLE | 2014 |
|
RU2547692C1 |
METHOD OF TREATING ISCHEMIC HEART DISEASE WITH DISTAL OR DIFFUSE AFFECTION OF CORONARY ARTERIES | 2011 |
|
RU2481839C2 |
METHOD FOR CORRECTING POSTISCHEMIC COGNITIVE DYSFUNCTION | 2006 |
|
RU2315618C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF EXTREMITY ISCHEMIA INCLUDING IN L-NAME INDUCED NITROGEN OXIDE DEFICIENCY | 2010 |
|
RU2426174C1 |
METHOD FOR PREVENTING ISCHEMIC NEUROPATHY OF THE OPTIC NERVE BY CARBAMYLATED DARBEPOETIN IN EXPERIMENT | 2017 |
|
RU2643579C1 |
METHOD FOR PREVENTION OF ISCHEMIA OF RETINA EXPERIMENTALLY | 2013 |
|
RU2539630C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIA OF SKELETAL MUSCLE WITH RESVERATROL | 2012 |
|
RU2518965C1 |
AGENT FOR TREATMENT OF BRAIN ISCHEMIC INJURY | 2004 |
|
RU2288714C2 |
Authors
Dates
2013-10-20—Published
2012-03-28—Filed